198 related articles for article (PubMed ID: 34669981)
1. Alemtuzumab clearance, lymphocyte count, and T-cell chimerism after hematopoietic stem cell transplant in sickle cell disease.
Furstenau D; Peer CJ; Hughes TE; Uchida N; Tisdale J; Hall OM; Figg WD; Hsieh M
Pharmacotherapy; 2022 Jan; 42(1):14-22. PubMed ID: 34669981
[TBL] [Abstract][Full Text] [Related]
2. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation.
Bhoopalan SV; Cross SJ; Panetta JC; Triplett BM
Cancer Chemother Pharmacol; 2020 Dec; 86(6):711-717. PubMed ID: 33037919
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.
Hsieh MM; Kang EM; Fitzhugh CD; Link MB; Bolan CD; Kurlander R; Childs RW; Rodgers GP; Powell JD; Tisdale JF
N Engl J Med; 2009 Dec; 361(24):2309-17. PubMed ID: 20007560
[TBL] [Abstract][Full Text] [Related]
5. Early Myeloid Derived Suppressor Cells (eMDSCs) Are Associated With High Donor Myeloid Chimerism Following Haploidentical HSCT for Sickle Cell Disease.
Bhat DK; Olkhanud PB; Gangaplara A; Seifuddin F; Pirooznia M; Biancotto A; Fantoni G; Pittman C; Francis B; Dagur PK; Saxena A; McCoy JP; Pfeiffer RM; Fitzhugh CD
Front Immunol; 2021; 12():757279. PubMed ID: 34917079
[TBL] [Abstract][Full Text] [Related]
6. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA.
Mackinnon S; Barnett L; Bourhis JH; Black P; Heller G; O'Reilly RJ
Blood; 1992 Dec; 80(12):3235-41. PubMed ID: 1467526
[TBL] [Abstract][Full Text] [Related]
7. Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort study.
Dovern E; Aydin M; Hazenberg MD; Tang MW; Suijk EM; Hoogendoorn GM; Van Tuijn CFJ; Kerkhoffs JL; Rutten CE; Zeerleder SS; de la Fuente J; Biemond BJ; Nur E
Am J Hematol; 2024 May; ():. PubMed ID: 38733340
[TBL] [Abstract][Full Text] [Related]
8. Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease.
Saraf SL; Oh AL; Patel PR; Jalundhwala Y; Sweiss K; Koshy M; Campbell-Lee S; Gowhari M; Hassan J; Peace D; Quigley JG; Khan I; Molokie RE; Hsu LL; Mahmud N; Levinson DJ; Pickard AS; Garcia JG; Gordeuk VR; Rondelli D
Biol Blood Marrow Transplant; 2016 Mar; 22(3):441-8. PubMed ID: 26348889
[TBL] [Abstract][Full Text] [Related]
9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
10. Matched related hematopoietic cell transplant for sickle cell disease with alemtuzumab: the Texas Children's Hospital experience.
John TD; Friend B; Yassine K; Sasa G; Bhar S; Salem B; Omer B; Craddock J; Doherty E; Martinez C; Heslop HE; Krance RA; Leung K
Bone Marrow Transplant; 2021 Nov; 56(11):2797-2803. PubMed ID: 34274957
[TBL] [Abstract][Full Text] [Related]
11. Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease.
Saraf SL; Oh AL; Patel PR; Sweiss K; Koshy M; Campbell-Lee S; Gowhari M; Jain S; Peace D; Quigley JG; Khan I; Molokie RE; Mahmud N; Gordeuk VR; Rondelli D
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1759-1765. PubMed ID: 29656137
[TBL] [Abstract][Full Text] [Related]
12. Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells.
Grimaldi F; Potter V; Perez-Abellan P; Veluchamy JP; Atif M; Grain R; Sen M; Best S; Lea N; Rice C; Pagliuca A; Mufti GJ; Marsh JCW; Barber LD
Biol Blood Marrow Transplant; 2017 Feb; 23(2):293-299. PubMed ID: 27816648
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure.
Chewning JH; Castro-Malaspina H; Jakubowski A; Kernan NA; Papadopoulos EB; Small TN; Heller G; Hsu KC; Perales MA; van den Brink MR; Young JW; Prockop SE; Collins NH; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2007 Nov; 13(11):1313-23. PubMed ID: 17950918
[TBL] [Abstract][Full Text] [Related]
14. Case report: Successful treatment with daratumumab for pure red cell aplasia in a patient with mixed lymphoid chimerism after ABO-mismatched stem cell transplant for sickle cell disease.
Dovern E; Biemond BJ; Nur E
Front Immunol; 2023; 14():1212007. PubMed ID: 37426651
[TBL] [Abstract][Full Text] [Related]
15. Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients.
Bhatt ST; Bednarski JJ; Berg J; Trinkaus K; Murray L; Hayashi R; Schulz G; Hente M; Grimley M; Chan KW; Kamani N; Jacobsohn D; Nieder M; Hale G; Yu L; Adams R; Dalal J; Pulsipher MA; Haut P; Chaudhury S; Davis J; Jaroscak J; Andreansky M; Willert J; Shenoy S
Biol Blood Marrow Transplant; 2019 Mar; 25(3):556-561. PubMed ID: 30321596
[TBL] [Abstract][Full Text] [Related]
16. Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.
Guilcher GMT; Truong TH; Saraf SL; Joseph JJ; Rondelli D; Hsieh MM
Semin Hematol; 2018 Apr; 55(2):87-93. PubMed ID: 29958564
[TBL] [Abstract][Full Text] [Related]
17. BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions.
Burney C; Wadhera K; Breslin P; Pearce R; Wells M; Alajangi R; Protheroe R; Marks DI; Griffin J; Robinson S
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2271-2278. PubMed ID: 32890747
[TBL] [Abstract][Full Text] [Related]
18. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
Fu H; Xu L; Liu D; Liu K; Zhang X; Chen H; Chen Y; Han W; Wang Y; Wang J; Wang F; Huang X
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1176-82. PubMed ID: 24747336
[TBL] [Abstract][Full Text] [Related]
19. Post-Transplant CD34
Chandra S; Bleesing JJ; Jordan MB; Grimley MS; Khandelwal P; Davies SM; Edwards S; Leemhuis T; Marsh RA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1527-1529. PubMed ID: 29555312
[TBL] [Abstract][Full Text] [Related]
20. Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure.
Mohamedbhai SG; Edwards N; Morris EC; Mackinnon S; Thomson KJ; Peggs KS
Br J Haematol; 2012 Feb; 156(4):516-22. PubMed ID: 22171699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
